- Home
- TRGS vs GALT Comparison
TRGS vs GALT Comparison
Compare TRGS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.02
Company Overview
Basic Information| Metric | TRGS | GALT |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.6M | 297.0M |
| IPO Year | 2026 | 2008 |
Fundamental Metrics
Financial Performance| Metric | TRGS | GALT |
|---|---|---|
| Price | $9.95 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 29.7K | ★ 340.4K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $2.03 |
| 52 Week High | $9.97 | $7.13 |
Technical Indicators
Market Signals| Indicator | TRGS | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 59.90 |
| Support Level | N/A | $2.74 |
| Resistance Level | N/A | $4.35 |
| Average True Range (ATR) | 0.01 | 0.28 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 83.33 | 72.03 |
Price Performance
Historical Comparison TRGS
GALT
About TRGS TRG Latin America Acquisitions Corp. Class A Ordinary Shares
TRG Latin America Acquisitions Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.